1.
Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr. Bleeding, blood transfusion, and increased mortality
after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol.
2009; 53:2019–2027. https://doi.org/10.1016/j.jacc.2008.12.073 PMID: 19477350
2.
Chhatriwalla AK, Amin AP, Kennedy KF, House JA, Cohen DJ, Rao SV, et al. Association between
bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA. 2013;
309:1022–1029. https://doi.org/10.1001/jama.2013.1556 PMID: 23483177
3.
Numasawa Y, Kohsaka S, Miyata H, Kawamura A, Noma S, Suzuki M, et al. Safety of transradial
approach for percutaneous coronary intervention in relation to body mass index: a report from a Japanese multicenter registry. Cardiovasc Interv Ther. 2013; 28:148–156. https://doi.org/10.1007/s12928012-0138-8 PMID: 23054968
4.
Jolly SS, Yusuf S, Cairns J, Niemela¨ K, Xavier D, Widimsky P, et al. Radial versus femoral access for
coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011; 377:1409–1420. https://doi.org/10.1016/S01406736(11)60404-2 PMID: 21470671
5.
Valgimigli M, Gagnor A, Calabro´ P, Frigoli E, Leonardi S, Zaro T, et al. Radial versus femoral access in
patients with acute coronary syndromes undergoing invasive management: a randomised multicentre
trial. Lancet. 2015; 385:2465–2476. https://doi.org/10.1016/S0140-6736(15)60292-6 PMID: 25791214
6.
Kwok CS, Khan MA, Rao SV, Kinnaird T, Sperrin M, Buchan I, et al. Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Interv. 2015; 8:e001645.
https://doi.org/10.1161/CIRCINTERVENTIONS.114.001645 PMID: 25825007
7.
Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, et al. Incidence, prognostic
impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous
coronary intervention. JACC Cardiovasc Interv. 2011; 4:191–197. https://doi.org/10.1016/j.jcin.2010.
10.011 PMID: 21349458
8.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus
clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001–2015. https://
doi.org/10.1056/NEJMoa0706482 PMID: 17982182
9.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361:1045–1057. https://doi.org/
10.1056/NEJMoa0904327 PMID: 19717846
10.
Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding
risk in patients undergoing percutaneous coronary intervention. Circulation. 2019; 140:240–261.
https://doi.org/10.1161/CIRCULATIONAHA.119.040167 PMID: 31116032
11.
Natsuaki M, Morimoto T, Shiomi H, Yamaji K, Watanabe H, Shizuta S, et al. Application of the Academic
Research Consortium High Bleeding Risk Criteria in an all-comers registry of percutaneous coronary
intervention. Circ Cardiovasc Interv. 2019; 12: e008307. https://doi.org/10.1161/
CIRCINTERVENTIONS.119.008307 PMID: 31707804
12.
Post PN, Kuijpers M, Ebels T, Zijlstra F. The relation between volume and outcome of coronary interventions: a systematic review and meta-analysis. Eur Heart J. 2010; 31:1985–1992. https://doi.org/10.
1093/eurheartj/ehq151 PMID: 20511324
13.
Badheka AO, Patel NJ, Grover P, Singh V, Patel N, Arora S, et al. Impact of annual operator and institutional volume on percutaneous coronary intervention outcomes: a 5-year United States experience
(2005–2009). Circulation. 2014; 130:1392–1406. https://doi.org/10.1161/CIRCULATIONAHA.114.
009281 PMID: 25189214
14.
Inohara T, Kohsaka S, Yamaji K, Amano T, Fujii K, Oda H, et al. Impact of institutional and operator volume on short-term outcomes of percutaneous coronary intervention: a report from the Japanese Nationwide Registry. JACC Cardiovasc Interv. 2017; 10:918–927. https://doi.org/10.1016/j.jcin.2017.02.015
PMID: 28473114
15.
Sawano M, Yamaji K, Kohsaka S, Inohara T, Numasawa Y, Ando H, et al. Contemporary use and
trends in percutaneous coronary intervention in Japan: an outline of the J-PCI registry. Cardiovasc
Interv Ther. 2020; 35:218–226. https://doi.org/10.1007/s12928-020-00669-z PMID: 32440831
PLOS ONE | https://doi.org/10.1371/journal.pone.0261371 December 13, 2021
10 / 11
PLOS ONE
Variation in in-hospital mortality after PCI
16.
Inohara T, Kohsaka S, Spertus JA, Masoudi FA, Rumsfeld JS, Kennedy KF, et al. Comparative trends
in percutaneous coronary intervention in Japan and the United States, 2013 to 2017. J Am Coll Cardiol.
2020; 76:1328–1340. https://doi.org/10.1016/j.jacc.2020.07.037 PMID: 32912447
17.
Inohara T, Kohsaka S, Yamaji K, Ishii H, Amano T, Uemura S, et al. Risk stratification model for in-hospital death in patients undergoing percutaneous coronary intervention: a nationwide retrospective
cohort study in Japan. BMJ Open. 2019 May 22; 9:e026683. https://doi.org/10.1136/bmjopen-2018026683 PMID: 31122979
18.
Hess CN, Rao SV, McCoy LA, Neely ML, Singh M, Spertus JA, et al. Identification of hospital outliers in
bleeding complications after percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes.
2015; 8:15–22. https://doi.org/10.1161/CIRCOUTCOMES.113.000749 PMID: 25424242
19.
Silber JH, Williams SV, Krakauer H, Schwartz JS. Hospital and patient characteristics associated with
death after surgery. A study of adverse occurrence and failure to rescue. Med Care. 1992; 30:615–629.
https://doi.org/10.1097/00005650-199207000-00004 PMID: 1614231
20.
Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery.
N Engl J Med. 2009; 361:1368–1375. https://doi.org/10.1056/NEJMsa0903048 PMID: 19797283
21.
Wong SL, Revels SL, Yin H, Stewart AK, McVeigh A, Banerjee M, et al. Variation in hospital mortality
rates with inpatient cancer surgery. Ann Surg. 2015; 261:632–636. https://doi.org/10.1097/SLA.
0000000000000690 PMID: 24743604
22.
Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in Myocardial Infarction
(TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic
system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll
Cardiol. 1988; 11:1–11. https://doi.org/10.1016/0735-1097(88)90158-1 PMID: 3121710
23.
GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for
acute myocardial infarction. N Engl J Med. 1993; 329:673–682. https://doi.org/10.1056/
NEJM199309023291001 PMID: 8204123
24.
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123:2736–2747. https://doi.org/10.1161/CIRCULATIONAHA.110.009449
PMID: 21670242
25.
Sherwood MW, Wang Y, Curtis JP, Peterson ED, Rao SV. Patterns and outcomes of red blood cell
transfusion in patients undergoing percutaneous coronary intervention. JAMA. 2014; 311:836–843.
https://doi.org/10.1001/jama.2014.980 PMID: 24570247
PLOS ONE | https://doi.org/10.1371/journal.pone.0261371 December 13, 2021
11 / 11
...